Related Experiment Videos
Methodology for the rational development of methotrexate analogs in the clinic
B Leyland-Jones1, P J O'Dwyer, D F Hoth
1Investigational Drug Branch, National Cancer Institute, Bethesda, MD 20892.
Abstract:
This paper suggests a development plan for antifolate analogs, based upon disease classifications that the National Cancer Institute has successfully utilized for the development of anthracycline and platinum analogs. Diseases are classified according to the role of the parent compound in standard therapy: 1) those in which methotrexate is an important component of standard treatment strategies that have state-of-the-art effectiveness; 2) those in which methotrexate has antitumor activity but no clear role in standard state-of-the-art treatment strategies; and 3) those in which methotrexate has insufficient activity to warrant its use alone or in combination. Developmental plans are specified for each of these disease classes. Trimetrexate is used as a specific example for these plans, although this method of drug development is equally applicable to other methotrexate analogs.
Insights
This study proposes a novel development plan for antifolate analogs, using National Cancer Institute disease classifications. This strategy categorizes diseases based on methotrexate
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Antifolate analogs are crucial in cancer therapy.
- Methotrexate is a key antifolate with established roles in specific cancers.
- Existing drug development strategies can be adapted for antifolate analogs.
Purpose of the Study:
- To propose a structured development plan for antifolate analogs.
- To leverage National Cancer Institute (NCI) disease classifications for antifolate analog development.
- To outline specific developmental strategies based on disease-treatment roles.
Main Methods:
- Classification of diseases based on the role of methotrexate in standard therapy.
- Categorization into three distinct disease classes: state-of-the-art effectiveness, antitumor activity without clear role, and insufficient activity.
- Application of a development plan tailored to each disease class, exemplified by trimetrexate.
Main Results:
- A systematic approach for antifolate analog development is presented.
- Disease classification provides a framework for prioritizing and guiding drug development.
- Trimetrexate serves as a model compound for illustrating the proposed development plan.
Conclusions:
- The proposed disease classification system offers a rational basis for antifolate analog development.
- This strategy can optimize the development of new antifolate drugs, including trimetrexate and other analogs.
- The approach is adaptable and applicable to a broader range of antifolate drug discovery efforts.